[go: up one dir, main page]

Kallikreins

"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).


expand / collapse Publications
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
Below are the most recent publications written about "Kallikreins" by people in Profiles.
  1. A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nat Commun. 2024 Nov 06; 15(1):9587.
    View in: PubMed
  2. CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med. 2025 Jan 30; 392(5):458-467.
    View in: PubMed
  3. Serendipitous Discovery of T Cell-Produced KLK1b22 as a Regulator of Systemic Metabolism. Immunohorizons. 2023 06 01; 7(6):493-507.
    View in: PubMed
  4. COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications. Allergy Asthma Proc. 2021 Nov 01; 42(6):506-514.
    View in: PubMed
  5. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. J Urol. 2022 02; 207(2):324-332.
    View in: PubMed
  6. A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
    View in: PubMed
  7. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 11; 206(5):1147-1156.
    View in: PubMed
  8. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology. 2021 11; 157:102-106.
    View in: PubMed
  9. Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol. 2021 11; 18(11):643-668.
    View in: PubMed
  10. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 04 29; 11(1):9264.
    View in: PubMed